Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
Gastric cancer is a beast. Despite being the fourth most fatal cancer worldwide — killing nearly 770,000 people per year — drug developers have made little headway against it in decades. For most patients with metastatic disease, the first-line treatment is chemotherapy that offers an average overall survival of about 1 year. With Astellas’s recent filing of its claudin-18.2-targeted antibody zolbetuximab for regulatory approval in the USA, the EU and Japan, a new therapeutic option for a large subset of these patients is within reach.